AllianceBernstein
CADL icon

AllianceBernstein’s Candel Therapeutics CADL Stock Holding History

AllianceBernstein’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Sell
40,920
-28,190
-41% -$213K ﹤0.01% 3145
2026
Q1 		$390K Hold
69,110
– – ﹤0.01% 2762
2025
Q4 		$390K Hold
69,110
– – ﹤0.01% 2781
2025
Q3 		$352K Hold
69,110
– – ﹤0.01% 2865
2025
Q2 		$350K Buy
69,110
+58,450
+548% +$301K ﹤0.01% 2840
2025
Q1 		$60.2K Hold
10,660
– – ﹤0.01% 3114
2024
Q4 		$92.5K Hold
10,660
– – ﹤0.01% 3131
2024
Q3 		$73.9K Hold
10,660
– – ﹤0.01% 3157
2024
Q2 		$66.1K Buy
+10,660
New +$80K ﹤0.01% 3168

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AllianceBernstein's CADL Position: Q2 2026 in Review

AllianceBernstein reduced its Candel Therapeutics (CADL) stake by 41% in Q2 2026, selling an estimated $213K and leaving 40,920 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

AllianceBernstein first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. The position peaked at $390K in Q1 2026. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • AllianceBernstein held 40,920 shares of Candel Therapeutics worth $201K as of Q2 2026.
  • AllianceBernstein sold 28,190 Candel Therapeutics shares in Q2 2026, an estimated $213K.
  • Candel Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3145 holding.
  • AllianceBernstein first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • AllianceBernstein's Candel Therapeutics position peaked at $390K in Q1 2026.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.